Your browser doesn't support javascript.
loading
Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Nedved, Adrienne; Maddocks, Kami; Nowakowski, Grzegorz S.
Affiliation
  • Nedved A; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
  • Maddocks K; Arthur G. James Comprehensive Cancer Center, Ohio State University Wexner Medical Center, Columbus, OH, USA.
  • Nowakowski GS; Department of Pharmacy, Mayo Clinic, Rochester, MN, USA.
Oncologist ; 28(3): 199-207, 2023 03 17.
Article in En | MEDLINE | ID: mdl-36648324
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse Type of study: Guideline Limits: Aged / Humans Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country:
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Lymphoma, Non-Hodgkin / Lymphoma, Large B-Cell, Diffuse Type of study: Guideline Limits: Aged / Humans Language: En Journal: Oncologist Journal subject: NEOPLASIAS Year: 2023 Document type: Article Affiliation country: